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Abstract         
Rho-mediated inhibition of myosin light chain (MLC) phosphatase (MLCP), together with 
Ca2+-dependent MLC kinase activation, constitutes the major signaling mechanisms for vascular 
smooth muscle (VSM) contraction. We recently unveiled the involvement of Ca2+-induced, 
phosphoinositide 3-kinase (PI3K) class II-isoform (PI3K-C2)-dependent Rho activation and 
resultant Rho kinase-dependent MLCP suppression in membrane depolarization- and receptor 
agonists-induced contraction. It is unknown whether Ca2+- and PI3K-C2-dependent regulation 
of MLCP is altered in VSM of hypertensive animals and is involved in hypertension. Therefore, 
we studied the role of the Ca2+-PI3K-C2-Rho-MLCP pathway in spontaneously hypertensive 
rats (SHRs). PI3K-C2 was readily detected in various vascular beds of Wistar-Kyoto rats and 
activated by high KCl. High KCl also stimulated vascular Rho activity and phosphorylation of 
the MLCP regulatory subunit MYPT1 at Thr853 in a PI3K inhibitor wortmannin-sensitive manner. 
In mesenteric and other vessels of SHRs at the hypertensive but not prehypertensive stage, the 
activity of PI3K-C2 but not class I PI3K p110 was elevated with concomitant rises of Rho 
activity and Thr853-phosphorylation of MYPT1, as compared with normotensive controls. 
Infusion of the Ca2+ channel antagonist nicardipine reduced blood pressure with suppression of 
vascular activity of PI3K-C2-Rho and phosphorylation of MYPT1 in hypertensive SHRs. 
Infusion of wortmannin lowered blood pressure with inhibition of PI3K-C2-Rho activities and 
MYPT1 phosphorylation in hypertensive SHRs. These observations suggest that an increased 
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activity of the Ca2+-PI3K-C2-Rho signaling pathway with resultant augmented MLCP 
suppression contributes to hypertension in SHRs. The Ca2+- and PI3K-C2-dependent Rho 
stimulation in VSM may be a novel, promising target for treating hypertension. 
 


















Accumulated evidence shows that enhanced peripheral vascular constriction is an important 
component in human essential hypertension and other animal models of hypertension.1 Various 
contractile receptor agonists and mechanical strain induce vascular smooth muscle (VSM) 
contraction, contributing to vascular tone. Contractile stimuli induce an increase in the 
intracellular free Ca2+ concentration, which mediates myosin light chain kinase (MLCK) 
activation to result in phosphorylation of the 20 kDa myosin light chain (MLC) and the initiation 
of actin-myosin interaction.2,3 Various receptor agonists also activate the distinct signaling 
pathway comprising Rho and its effector Rho kinase via G12/13, which leads to inhibition of 
myosin light chain phosphatase (MLCP) through mechanisms involving Rho kinase-dependent 
phosphorylation of the MLCP-regulatory subunit MYPT1 at the inhibitory phosphorylation sites 
Thr853 and/or Thr696 (numbering of human MYPT1).2-9  Phosphorylation of MYPT1 at Thr853 is 
to the larger extent stimulated by receptor agonists in a Rho kinase-dependent manner compared 
with phosphorylation at Thr696.10,11 We and others previously demonstrated in VSM that 
membrane depolarization-induced Ca2+ influx elicits Rho activation and consequent Rho 
kinase-dependent phosphorylation of MYPT1 at Thr853 and to the lesser extent at Thr696 
(Ca2+-induced Ca2+-sensitization).11-14 The Ca2+-induced Rho activation and Rho 
kinase-dependent MLCP inhibition are dependent on phosphoinositide 3-kinase (PI3K) class II 
-isoform (PI3K-C2).11,15 This Ca2+-induced, PI3K-C2-dependent Rho activation mechanism 
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is also involved in receptor agonist-induced Rho stimulation.11, 15  Thus, in VSM stimulated by 
either receptor agonists or membrane depolarization, MLCK activation and MLCP inhibition 
synergistically act to induce effective MLC phosphorylation and contractile responses.                    
In our previous study11, we observed that administration of the PI3K inhibitor, wortmannin, 
into normal rats induced dose-dependent reductions in arterial blood pressure with suppression of 
vascular activities of PI3K-C2 and Rho and phosphorylation level of MYPT1, suggesting that 
PI3K-C2 plays a substantial role in vivo in maintaining vascular tone and blood pressure 
through regulating Rho and MLCP. Previous studies suggested that hyperactivity of Rho-Rho 
kinase pathway augments Ca2+-sensitivity of myofilaments in VSM of rat hypertensive models 
including spontaneously hypertensive rats (SHRs) and human hypertensive patients.9, 16-20 
However, it is totally unknown whether Ca2+-induced, PI3K-C2-dependent regulation of Rho 
and MLCP is altered in VSM of hypertensive animals and is involved in hypertension.  
In the present study, we studied the role of the Ca2+-PI3K-C2-Rho-MLCP pathway in 
hypertension by comparing vascular activities of PI3K-C2, Rho and MLCP between SHRs and 
normotensive Wistar-Kyoto (WKY) rats and examining the effects of the Ca2+-channel 
antagonist nicardipine and WMN on blood pressure and vascular activities of PI3K-C2, Rho 
and MLCP in SHRs. Our results show that vascular PI3K-C2 activity, Rho activity, and 
MYPT1 phosphorylation at Thr853 in blood vessels are all elevated in SHRs. Either nicardipine or 
wortmannin effectively reversed hyperactivities of PI3K-C2 and Rho and 
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hyperphosphorylation of MYPT1 in blood vessels with correction of hypertension. The 
observations suggest the critical role of the Ca2+-PI3K-C2-Rho-MLCP pathway in 
hypertension of SHRs. 
 
 
Materials and Methods 




The expression of PI3K-C2membrane depolarization-induced stimulation of PI3K-C2, Rho 
and MYPT1 phosphorylation, and their inhibition by wortmannin in various vascular beds of 
WKY rats  
We studied the expression of PI3K-C2 in various vascular beds of normotensive WKY rats. 
Western analysis readily detected PI3K-C2protein in all endothelium-denuded blood vessels 
examined, which included aorta, carotid artery, pulmonary artery, mesenteric artery, and femoral 
artery and vein (Figure 1A). These vascular beds also expressed class I PI3K p110. The PI3K 
inhibitor wortmannin inhibited high KCl membrane depolarization-induced contraction of these 
blood vessels with the similar dose-response relationships (Figure 1 B). The structurally different 
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PI3K inhibitor LY294002 also inhibited contraction in a dose-dependent manner (Fig. S1). 
Wortmannin suppressed PI3K-C2 activity in aortae with the similar dose-response relationship 
as that for inhibition of the contractile response (Fig. S2). In the employed in vitro assay 
condition for immunoprecipitated PI3K-C2activitywe confirmed a linear time-dependent 
increase in the PI3K-C2 product (Fig. S3). High KCl stimulation of aortae and mesenteric 
arteries induced 1.8-2.0 fold increases in the activity of PI3K-C2immunoprecipitated from the 
blood vessels, which were abolished by pretreatment of vessels with wortmannin (Figure 2 A). 
High KCl also increased the amounts of GTP-bound, active RhoA (GTP-Rho) (Figure 2 B). 
Consistent with this, high KCl stimulated phosphorylation at Thr853 of MYPT1 in aortae and 
mesenteric arteries (Figure 2 C). Wortmannin inhibited KCl-induced increases in both RhoA 
activity and MYPT1 phosphorylation at Thr853. High KCl did not change phosphorylation at 
Thr696 of MYPT1 in aortae (Figure S4 A). Wortmannin, which also inhibits MLCK in a 
ATP-sensitive manner21, did not inhibit MLCK in permeabilized VSM cells or isolated MLCK at 
a physiological mM order of ATP concentration (Fig. S5). 
 
Increases in the activities of PI3K-C2 and Rho and phosphorylation of MYPT1 in aortae of 
hypertensive SHRs but not prehypertensive young SHRs  
Twelve-week-old SHRs exhibited a marked increase in systolic blood pressure compared with 
age-matched WKY rats (180±2 (n=13) in SHRs vs. 113±2 mm Hg (n=13) in WKY rats, p<0.01). 
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PI3K-C2 activity in aortae of SHRs was 2.7-fold higher than in WKY rats (Figure 3A). The 
expression level of PI3K-C2 protein in the vessels was similar between SHRs and WKY rats 
when the same amounts of the tissue protein were analyzed (Figure 3 A, middle panel of Western 
blots). In contrast, the activity and protein expression level of class I PI3K p110 in blood 
vessels were similar between SHRs and WKY rats (Figure 3 B). We compared vascular 
PI3K-C2 activity in young 4-week-old SHRs at the prehypertensive stage with that of 
12-week-old hypertensive SHRs. PI3K-C2 activity in 4-week-old SHRs (systolic blood 
pressure 117±2 mm Hg (n=4)) was similar to that in normotensive 12-week-old WKY rats 
(110±4 mm Hg (n=4)), and lower than in 12-week-old SHRs (176±2 mm Hg, n=4) whereas the 
expression level of PI3K-C2 protein in vessels was not different among the three rat groups 
(Figure 3 C). In isolated 12-week-SHR aortae, both the basal and KCl-stimulated PI3K-C2 
activities were higher compared with WKY vessels (Figure S6). The amount of GTP-Rho in 
12-week-old SHRs was 2.2-fold higher than in the age-matched WKY rats (Figure 3 D), which is 
consistent with the report by Seko et al.18 Consistently, the extent of phosphorylation at Thr853 of 
MYPT1 were elevated in aortae of 12-week-old SHRs than in age-matched WKY rats (Figure 3 
E) whereas phosphorylation at Thr696 of MYPT1 was not different between WKY rats and SHRs 
(Figure S4 B). These observations suggest that MLCP in VSM is suppressed in hypertensive 




Ca2+ channel blocker nicardipine lowers systolic blood pressure, the activities of PI3K-C2 and 
Rho, and MYPT1 phosphorylation in aortae of hypertensive SHRs 
We previously showed that PI3K-C2 is stimulated in a Ca2+-dependent manner in isolated VSM 
contracted by either membrane depolarization or receptor agonists.11, 15 Therefore, we tested the 
in vivo effects of the Ca2+-channel antagonist nicardipine on the activities of PI3K-C2, Rho, 
and MLCP in vessels of SHRs. Infusion of either nicardipine or hydralazine, the latter of which 
was used as a control anti-hypertensive, induced similar magnitudes of decreases in systolic 
blood pressure with the maximal declines of about 85 mm Hg and 80 mm Hg, respectively, at 10 
min after infusion in 12-week-old SHRs (Figure 4 A). Nicardipine but not hydralazine reduced 
vascular PI3K-C2 activity in aortae of SHRs to the level in age-matched WKY control rats 
(Figure 4 B). Nicardipine also lowered Rho activity and Thr853 phosphorylation levels of MYPT1 
in aortae of SHR nearly to the levels in WKY rats (Figure 4 C and 4 D). Nicardipine did not 
change Thr696 phosphorylation of MYPT1 (Figure S4 B). Hydralazine did not significantly 
inhibit Rho activity or phosphorylation of MYPT1 in SHRs.  
 
Wortmannin lowers systolic blood pressure, the activities of PI3K-C2 and Rho, and MYPT1 
phosphorylation in aortae of hypertensive SHRs 
In normotensive rats, we previously showed that the PI3K inhibitor wortmannin reduced blood 
pressure due to its direct vasodilator effect.11, 22 We tested the effects of wortmannin infusion on 
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blood pressure and vascular activities of PI3K-C2, Rho and MLCP in SHRs. Wortmannin 
substantially lowered systolic blood pressure with the maximal decline of about 70 mm Hg at 10 
min after infusion in 12-week-old SHRs (Fig. 5 A). Wortmannin infusion reduced enhanced 
activities of PI3K-C2 activity and Rho activity and Thr853 phosphorylation of MYPT1 in aortae 
of SHRs (Figure 5 B-D). Wortmannin did not affect Thr696 phosphorylation of MYPT1 (Figure 
S4 B). 
 
Nicardipine and wortmannin inhibit the activities of PI3K-C2 and Rho and phosphorylation of 
MYPT1 in mesenteric arteries of hypertensive SHRs 
We studied the effects of infusions of nicardipine and wortmannin on the activity of 
PI3K-C2-Rho-MLCP pathway in the resistance artery, mesenteric artery. The infusions of the 
same doses of either nicardipine or wortmannin as in Figures 4 and 5 suppressed 
PI3K-C2activity in mesenteric artery with the declines of blood pressure (Figure 6 A and 6 B). 
Nicardipine and wortmannin also decreased the amounts of GTP-Rho and MYPT1 
phosphorylation at Thr853 (Figure 6 C and 6 D). Similarly as in aortae, phosphorylation at Thr696 
of MYPT1 in mesenteric arteries was not different between WKY rats and SHRs (Figure S4 C). 
   These observations collectively suggest that Ca2+-dependent PI3K-C2 stimulation in VSM 





High blood pressure is a disease affecting 20-30% of the world’s adult population.23  Although 
pathogenic mechanisms of hypertension are not completely elucidated, it is widely accepted that 
increased peripheral VSM contraction is an important mechanism underlying the development of 
hypertension.1  VSM tone is regulated by multitudes of contractile and relaxing stimuli 
including neurotransmitters, circulating vasoactive hormones, locally produced vasoactive 
substances, and mechanical forces.1, 3, 4  The involvement of hyperactivities of these contractile 
stimuli in hypertension was intensively investigated previously. However, possible alterations of 
the intracellular contractile signaling in VSM of hypertensive animals are only poorly understood. 
Ca2+ is the primary intracellular messenger to determine contractile state of VSM through 
regulating MLCK-catalyzed phosphorylation of MLC.2, 4 Recently, we found that Ca2+ also 
activates the small GTPase Rho via PI3K-C2 to result in MLCP suppression.11-12, 15, 22, 24 The 
identification of this second Ca2+-activated contractile signaling pathway comprising 
PI3K-C2-Rho-MLCP implies that Ca2+ induces stimulation of MLC phosphorylation and 
contraction through both MLCK activation and MLCP inhibition.13, 14, 23  
   In the present study, we showed that PI3K-C2 is widely expressed in various vascular beds 
including aorta, the muscular and smaller resistance arteries, and vein (Fig. 1 A). In vessels 
isolated from these vascular beds, wortmannin inhibited membrane depolarization-induced 
contraction with the similar dose-response relationships among these vessels (Fig. 1 B). These 
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observations suggest that a PI3K-dependent contractile mechanism is operating in various 
vascular beds of rats. The observed dose-response relationship is similar to that observed in 
rabbit blood vessels of our previous study11, suggesting that a responsible PI3K is relatively less 
sensitive to wortmannin, which is a characteristic of PI3K-C2but not any other PI3K 
member.25 Consistent with this, wortmannin inhibited KCl-induced PI3K-C2 activation in the 
blood vessels with the similar dose-response relationship to that for contraction (Figure S2). A 
previous study21 demonstrated a MLCK inhibitor activity of wortmannin. Our previous 
observations11, 15 and present results together suggest that the major in vivo target of wortmannin 
in inhibition of VSM contraction is PI3K-C2 but not MLCK in VSM although it is not totally 
precluded that wortmannin inhibition of MLCK to some extent contributes to inhibition of 
contraction. 
SHRs are the hypertension model that at least in part involves blood vessel hypercontractility 
and increased vascular Rho activity through mechanisms including endothelial dysfunction, 
increased sympathetic tone, and/or abnormalities inherent in VSM.1, 16-18, 23  The present 
observations suggest the link of PI3K-C2, which we previously showed to be involved in 
Ca2+-induced stimulation of Rho- and Rho kinase-dependent MLCP inhibition,11, 15 to an 
increased Rho activity in vessels of hypertensive SHRs: first, the activity of PI3K-C2but not 
class I PI3K p110 in mesenteric arteries and aortae of hypertensive SHRs is elevated with 
concomitant increased Rho activity and MYPT1 phosphorylation as compared with 
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normotensive, age-matched WKY rats (Figs. 3 and 6). Secondly, PI3K-C2 is activated by 
membrane depolarization-induced Ca2+ entry in blood vessels with the larger extent of activation 
in SHRs (Fig. 2 and Fig. S6). Thirdly, blockade of Ca2+ entry by nicardipine infusion suppressed 
vascular activities of PI3K-C2and Rho with a decline of blood pressure in hypertensive SHRs 
(Figs. 3 and 6). Finally, infusion of the PI3K inhibitor wortmannin into hypertensive SHRs 
suppressed vascular Rho activity with a decrease in blood pressure. Moreover, our data in 
nicardipine- or wortmannin-administered hypertensive SHRs show that inhibition of vascular 
Rho activity was accompanied by reductions in phosphorylation of MYPT1 at the inhibitory site 
Thr853 in hypertensive SHRs. Thus, these findings suggest that elevated vascular Rho activity 
results in augmented suppression of MLCP and consequently contributes to increased vascular 
contraction and hypertension in SHRs. This is the first evidence for an altered activity of 
vascular PI3K-C2Rho-MLCP axis in hypertension and the involvement of this axis in 
hypertension. We previously showed that wortmannin infusion into normotensive rats resulted in 
inhibition of vascular PI3K-C2 with reductions in Rho activity, MYPT1 phosphorylation, and 
blood pressure.12 These observations together suggest that PI3K-C2in VSM is involved in the 
blood pressure regulation under both the physiological and pathological conditions through its 
effects on the Rho-MLCP pathway. It is unknown at present how PI3K-C2is involved in Rho 
activation in VSM.  
   In isolated VSM, PI3K-C2 is activated by Ca2+ entry across the plasma membrane 
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particularly through L-type voltage-dependent Ca2+ channels (Fig. 2 A).12 The inhibitory effects 
of nicardipine infusion on not only PI3K-C2 activity but also Rho and MYPT1 phosphorylation 
indicated that Ca2+ influx is a major regulator of the PI3K-C2-Rho-MLCP pathway in blood 
vessels of hypertensive SHRs in vivo. Several lines of evidence indicates that Ca2+ entry through 
L-type of Ca2+ channels in VSM of hypertensive SHRs is elevated, which plays a critical role in 
elevation of vascular tone. For example, Ca2+ channel blockers at doses that had little 
hypotensive effect in normotensive WKY rats profoundly reduced blood pressure in hypertensive 
SHRs.26 VSM isolated from hypertensive SHRs shows augmented contraction in responses to 
stimulation of voltage-dependent Ca2+ channels by Bay k 8644.27  In addition, blood vessels 
from SHRs exhibit upregulation of L-type of Ca2+ channel expression.28 Differently from adult 
hypertensive SHR, vascular PI3K-C2 activity in young prehypertensive SHRs, in which 
alterations in Ca2+ channel activity are not detected,26 was not elevated compared with 
normotensive WKY rats (Fig. 3). Hence, increased vascular PI3K-C2 activity in hypertensive 
SHRs may be secondary to increased Ca2+ entry through L-type of Ca2+ channels.  
Unlike the Ca2+ channel antagonist nicardipine, the vasodilator hydralazine was nearly 
ineffective in inhibiting PI3K-C2-MLCP pathway but with a marginal effect on Rho (Fig. 4). 
Although the molecular mechanism of the vasodilator effect of hydralazine is not yet completely 
defined, available evidence suggests that the major site of hydralazine action is inhibition of 
inositol-1,4,5-trisphosphate-induced Ca2+ release from the sarcoplasmic reticulum.29 Relative 
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ineffectiveness of hydralazine on the PI3K-C2-Rho pathway may suggest that PI3K-C2 in 
VSM is more sensitive to Ca2+ entry across the plasma membrane than Ca2+ mobilized from the 
intracellular Ca2+ store in vivo. Because upregulation of PI3K-C2 activity in blood vessels from 
hypertensive rats is still detectable in the immunoprecipitation-lipid kinase assay after tissue 
homogenization in the presence of a Ca2+ chelator, the stimulatory effect of Ca2+ on the 
PI3K-C2-Rho pathway is likely indirect. It remains to be clarified how increased Ca2+ entry 
brings about stimulation of PI3K-C2 activity in VSM. The previous investigation17 showed that 
the Ca2+-sensitivity of myofilaments is increased in -escin-permeabilized artery from SHRs. It 
is interesting to examine possible alterations of the PI3K-C2-Rho-MLCP pathway in 
-escin-permeabilized artery from SHRs. 
 
Perspectives 
The present study demonstrated a rise in the activity of PI3K-C2in mesenteric arteries and 
other vessels of hypertensive SHRs compared with normotensive control rats and 
pre-hypertensive SHRs. Increased PI3K-C2activity brought about stimulation of Rho and 
consequently augmented MLCP suppression in blood vessels. Ca2+ entry plays a critical role in 
the altered activity of PI3K-C2-Rho-MLCP pathway in vivo in hypertensive SHRs. The 
correction of the alterated activity of Ca2+-PI3K-C2-Rho-MLCP leads to lowering of blood 
pressure in SHRs, suggesting a causal link of this pathway to development of hypertension in 
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SHRs and the possibility that the pathway may be a promising molecular target for novel, 
anti-hypertensive drugs. The present study also provided novel mechanistic insights into the role 
of Ca2+ in contraction of VSM and the action of a Ca2+ channel antagonist.       
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Figure 1. Expression of PI3K-C2 protein in various vascular beds of rats and wortmannin 
sensitivity of KCl membrane depolarization-induced contraction. A, Six different segments of 
endothelium-denuded blood vessels isolated from 10-week-old WKY rats were analyzed for the 
expression of PI3K-C2, class I PI3K p110, and -smooth muscle actin (-SMA) as internal 
control by Western blot analysis. A; artery, V; vein. B, Isometric tension of various vascular 
segments stimulated with 60 mM KCl in the presence of indicated concentractions of 
wortmannin. Wortmannin (WMN) was added 60 min prior to KCl stimulation. The data are 
expressed as means±SE of 4 values.  
 
Figure 2. KCl-induced stimulation of activities of PI3K-C2 and Rho and phosphorylation of 
MYPT1 and their inhibition by wortmannin in aortae and mesenteric arteries of WKY rats. 
Denuded aortae or mesentery arteries were stimulated with 60 mM KCl for 5 min (A, B) or 10 
min (C) after pretreatment with 1 μM WMN for 1 h. Vessels were quickly isolated from WKY 
rats, rapidly frozen as described in “Materials and Methods”, and analyzed for PI3K-C2 
activity (A), the amounts of GTP-bound RhoA (GTP-Rho) (B), and phosphorylation of MYPT1 
(C) by the immunoprecipitation kinase assay for PI3K assay, the pull-down assay for GTP-Rho, 
and Western blotting using anti-phospho (Thr853)-MYPT1. Portions of tissue homogenates were 
also analyzed for protein amounts of PI3K-C2 and -SMA (A), RhoA (B), and total 
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MYPT1(C), and shown in the lower panels of Western blots. Values are means±SE. The numbers 
in parentheses on the top of bars indicate the numbers of analyzed rats.  
 
Figure 3. Stimulation of activities of PI3K-C2 and Rho and phosphorylation of MYPT1 in 
aortae of SHRs.  Aortae were quickly isolated from SHRs and WKY rats of indicated ages, 
rapidly frozen as described in “Materials and Methods”, and analyzed for PI3K-C2 activity (A 
and C), PI3K-p110 activity (B), and the amounts of GTP-bound RhoA (GTP-Rho) (D), and 
phosphorylation of MYPT1 (E) by the immunoprecipitation kinase assay for PI3K assay, the 
pull-down assay for GTP-Rho, and Western blotting using anti-phospho (Thr853)-MYPT1. 
Portions of tissue homogenates were also analyzed for protein amounts of PI3K-C2 (A and C), 
PI3K-p110 (B), -SMA (A-C), RhoA (D), and total MYPT1(E), and shown in the lower panels 
of Western blots. In (C), 4-week (wk)-old SHRs at the prehypertensive stage, 12-wk-old 
hypertensive SHRs and 12-wk-old normotensibe WKY rats were analyzed. Values are means±SE. 
The numbers in parentheses on the top of bars indicate the numbers of analyzed rats. The 
symbols * and ** denote statistical significance at the level of p0.05 and p<0.01, respectively, 
compared with “WKY” and 4-week SHRs in C. 
 
Figure 4. Ca2+ channel blocker nicardipine lowers the activities of PI3K-C2 and Rho, and 
phosphorylation of MYPT1 in aortae of SHRs.  Nicardipine (NIC) (1 mg/kg BW), hydralazine 
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(HDZ) (10 mg/kg BW) or vehicle solution were infused through the tail vein of conscious 12 
week-old SHR rats. 10 min later, rats were sacrificed and the blood vessels were isolated and 
analyzed as in Fig. 1. (A) systolic blood pressure (BP) at 10 min after infusion. (B) PI3K-C2 
activity. (C) the amounts of GTP-Rho. (D) phosphorylation of MYPT1 at Thr853. Values are 
means±SE. The symbols * and ** denote statistical significance at the levels of p0.05 and 
p0.01, respectively, compared with WKY rats. The symbol †† denotes statistical significance at 
the level of p0.01 compared with SHRs receiving vehicle. 
 
Figure 5. Wortmannin lowers the activities of PI3K-C2 and Rho, and phosphorylation of 
MYPT1 in aortae of SHRs.  Wortmannin (WMN) (5 mg/kg BW) or vehicle solution was 
infused through the tail vein of conscious 12 week-old SHRs. (A) systolic blood pressure (BP) at 
10 min after infusion. (B) PI3K-C2 activity. (C) the amounts of GTP-Rho. (D) phosphorylation 
of MYPT1 at Thr853. Values are means±SE. The symbol † denotes statistical significance at the 
level of p0.05 compared with SHRs receiving vehicle. 
 
Figure 6.  Infusion of nicardipine and wortmannin lower the activities of PI3K-C2 and Rho, 
and phosphorylation of MYPT1 in mesenteric arteries of SHRs. Nicardipine, wortmannin or 
vehicle solution were infused through the tail vein of conscious 12-week-old SHRs and 
age-matched WKY rats and analyzed as described in Figures 4 and 5. (A) systolic blood pressure 
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(BP) at 10 min after infusion. (B) PI3K-C2 activity. (C) the amounts of GTP-Rho. (D) 
phosphorylation of MYPT1 at Thr853. Values are means±SE. The symbols * and †denote 
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